KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Short term Debt (2016 - 2025)

Historic Short term Debt for Halozyme Therapeutics (HALO) over the last 11 years, with Q3 2025 value amounting to $710.7 million.

  • Halozyme Therapeutics' Short term Debt changed N/A to $710.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $710.7 million, marking a year-over-year change of. This contributed to the annual value of $13.3 million for FY2022, which is 8508.82% down from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Short term Debt is $710.7 million.
  • Over the past 5 years, Halozyme Therapeutics' Short term Debt peaked at $710.7 million during Q3 2025, and registered a low of $13.3 million during Q3 2022.
  • For the 3-year period, Halozyme Therapeutics' Short term Debt averaged around $142.5 million, with its median value being $89.3 million (2021).
  • In the last 5 years, Halozyme Therapeutics' Short term Debt surged by 301444.56% in 2021 and then plummeted by 8508.82% in 2022.
  • Quarter analysis of 3 years shows Halozyme Therapeutics' Short term Debt stood at $89.4 million in 2021, then plummeted by 85.09% to $13.3 million in 2022, then skyrocketed by 5229.87% to $710.7 million in 2025.
  • Its Short term Debt was $710.7 million in Q3 2025, compared to $13.3 million in Q4 2022 and $13.3 million in Q3 2022.